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Abstract
Purpose The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological 
cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive 
bladder cancer (NMIBC).
Methods A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients 
administered adjuvant intravesical Bacillus Calmette–Guérin (BCG) immunotherapy with maintenance were included. Mul-
tivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression.
Results After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.89%) were negative. 
During follow-up, 678 (64.82%) suffered recurrence, and 303 (30%) progression, 150 (14.34%) died of all causes, and 77 
(7.36%) died of bladder cancer. At multivariate analysis, tumor size (hazard ratio [HR]:1.3; p = 0.001), and multifocality 
(HR:1.24; p = 0.004) were significantly associated with recurrence (c-index for the model:55.98). Overweight (HR: 4; 
p < 0.001) and obesity (HR:5.33 p < 0.001) were significantly associated with an increased risk of recurrence. Addition of 
the BMI to a model that included standard clinicopathological factors increased the C-index by 9.9. For progression, we 
found that tumor size (HR:1.63; p < 0.001), multifocality (HR:1.31; p = 0.01) and concomitant CIS (HR: 2.07; p < 0.001) 
were significant prognostic factors at multivariate analysis (C-index 63.8). Overweight (HR: 2.52; p < 0.001) and obesity 
(HR: 2.521 p < 0.001) were significantly associated with an increased risk of progression. Addition of the BMI to a model 
that included standard clinicopathological factors increased the C-index by 1.9.
Conclusions The BMI could have a relevant role in the clinical management of T1G3 NMIBC, if associated with bladder 
cancer recurrence and progression. In particular, this anthropometric factor should be taken into account at initial diagnosis 
and in therapeutic strategy decision making.
Keywords Bladder cancer · Body mass index · Obesity · Prognosis
Introduction
Obesity is a growing global health burden. A recently pub-
lished meta-analysis showed that the number of obese sub-
jects has significantly increased in the last three decades [1]. 
Unfortunately, obesity is associated with a higher incidence 
and aggressiveness of several type of cancers, such as breast, 
prostate, ovarian, gastric, renal and colon cancers [2]. Data 
on the relationship between obesity and bladder cancer are 
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conflicting. Some authors reported that obesity is associated 
with a worse clinical outcome of bladder cancer patients, 
whereas other studies concluded that the body mass index 
(BMI) is not linked to worse oncological outcomes of these 
patients [3–6]. At the initial diagnosis, most patients pre-
sent non-muscle-invasive bladder cancer (NMIBC), gener-
ally treated with transurethral resection of the bladder tumor 
(TURBT), followed in some cases by intravesical therapy 
[7]. However, about 60% of these patients experience recur-
rence and about 10% progress to muscle-invasive disease at 
5 years; the set of T1 high-grade (HG) NMIBCs shows the 
highest rate of progression [7].
In this regard, a recent meta-analysis of 14 prospective 
cohort studies involving 12,642 cases showed a nonlinear 
positive relationship between the BMI and bladder cancer 
(SRR = 1.03, 95% CI 1.01–1.06, P-nonlinearity = 0.031), 
suggesting that each 5 kg/m2 increase of the BMI corre-
sponded to a 3.1% increase of bladder cancer risk, especially 
when the BMI exceeded 30 kg/m2.
However, knowledge of the role of the BMI in patients 
with high-risk NMIBC is limited by retrospective data [8] 
and no study design standardization (i.e., lack of data on 
repeat transurethral resection of the bladder and the intra-
vesical therapy protocol).
In this study, we aimed to evaluate the impact of the BMI 
on survival in patients with high-risk non-muscle-invasive 
bladder cancer.
Patients and methods
A total of 1155 primary T1G3 NMIBC patients admin-
istered TURBT from 13 academic institutions between 
January 1st, 2002 and December 31st, 2012 were retro-
spectively analyzed. Inclusion criteria included Bacillus 
Calmette–Guérin (BCG) treatment with maintenance; 
109 patients treated with intravesical chemotherapy were 
excluded. Demographic, clinical and pathological data 
were collected and entered in a computerized database. 
Histology was performed by experienced uro-pathologists 
at each institution. Tumors were histologically classified 
according to the TNM system of Union for International 
Cancer Control (UICC) and to the 1973 World Health 
Organization (WHO) grading system. The re-TURBT 
Protocol included tumor scar and base resection, together 
with the bladder neck (for CIS) and red bladder patches. 
Re-TURBT was performed within 6 weeks after the first 
TURBT [9]. Each patient underwent adjuvant intravesical 
BCG immunotherapy according to the European Asso-
ciation of Urology (EAU) recommendations, consisting 
of a 6-week induction course of intravesical BCG fol-
lowed by the standard maintenance scheme, namely intra-
vesical BCG—standard dose—once a week for 3 weeks, 
administered at 3, 6, 12, 18, 24, 30 and 36 months from the 
start of therapy. In total, 303 (29%) of patients completed 
the treatment protocol as planned [10]. The upper urinary 
tract was evaluated using radiological imaging in all sub-
jects yearly or when clinically indicated to exclude the 
presence of concomitant carcinoma. The BMI was defined 
as the weight in kilograms divided by the square height in 
meters (kg/m2) using pre-TURBT data, and patients were 
assigned according to the International Classification of 
adults to the underweight, overweight and obesity group 
according to the BMI [11].
Follow‑up
Patients were followed up every 3 months according to 
EAU guidelines with cystoscopy and urinary cytology 
[10]. Endpoints were time to recurrence, progression, 
overall and cancer-specific survival. Recurrence was 
defined as the appearance of any tumor, and progression 
as muscle-invasive disease during follow-up. Patients with 
muscle-invasive disease on re-TUR and those who failed 
BCG underwent radical cystectomy [12].
Statistical analysis
Continuous variables were presented as median and inter-
quartile range (IQR) and differences between groups were 
assessed with the Kruskal–Wallis test or Mann–Whitney U 
test as appropriate. Categorical variables were tested with 
the Chi square test or Fisher exact test.
Multivariable Cox regression analysis was performed to 
identify predictive factors of recurrence and progression, 
using the variables collected.
For statistical analysis, we assigned patients to 
the underweight (BMI < 18.5), normal weight (BMI 
18.5–24.99), overweight (BMI 25–29.99) and obese 
(BMI ≥ 30) categories [11]. Kaplan–Meier curves were 
applied to calculate the association between BMI and 
recurrence-free survival (RFS), progression-free survival 
(PFS), cancer-specific survival (CSS) and overall survival 
(OS). Log-rank test was used to verify statistical signifi-
cance between curves.
All statistical analyses were completed using Stata soft-
ware, version 14 (StataCorp. 2015. Stata Statistical Soft-
ware: Release 14. College Station, TX: StataCorp LP.). 
For all statistical comparisons, a value of p < 0.05 was 
considered statistically significant.
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Results
Association of the BMI with clinical and pathological 
features
Median age was 71.0 years [Interquartile Range (IQR) 
65.0–78.0] and median BMI was 27.0 (IQR 24.0–29.0). 
As to the BMI distribution, 22 patients (2.1%) had a 
BMI < 18.5, 326 (31.2%) a BMI > 18.5 −  < 24.99, 474 
(45.3%) a BMI > 25 −  < 30 and 224 patients (21.4%) a 
BMI ≥ 30. Gender distribution was 82.6% (864) males and 
17.4% (182) females. Of the whole cohort, 221 patients 
(22.13%) had previously received chemotherapy instilla-
tion, 53 (5.07%) Epirubicin and 168 (14.54%) Mitomycin. 
After re-TURBT, 288 (27.53%) showed residual high-
grade NMIBC, while 867 (82.89%) were negative. All 
patients received BCG immunotherapy; median duration 
of the regimen was 12.0 months (IQR 6.0–36.0).
Table 1 lists the baseline characteristics of the study 
cohort according to the BMI. A larger proportion of patients 
with a BMI ≥ 25  kg/m2 were current smokers (51.3%, 
p < 0.001) compared to normal BMI or underweight patients. 
Tumor characteristics did not differ between BMI groups.
Association of BMI with recurrence and progression
Within a median time of 26  months (IQR 9–47), 678 
(64.82%) patients suffered recurrence, and within a median 
time of 43 months (IQR 36–58), 303 (30%) patients under-
went progression. Kaplan–Meier survival analysis showed 
that overweight and obese patients had a significantly 
reduced recurrence-free survival (RFS) as compared to 
normal weight or underweight patients (p < 0.001, Fig. 1a). 
Five-year RFS was 69.4% (CI 63.5–74.5) in patients with 
Table 1  Association of clinical 
and pathologic features with 
BMI in 1046 patients treated 
with BCG after primary T1G3 
NMIBC
Bold values identify statistically significant variables
BCG Bacillus Calmette–Guérin, NMIBC non-muscle-invasive bladder cancer, CIS carcinoma in  situ, BC 
bladder cancer, BMI Body mass index
BMI 18.5–24.99 BMI < 18.5 BMI 25–29.99 BMI ≥ 30 p
Total, n (%) 326 (31.2) 22 (2.1) 474 (45.3) 224 (21.4)
Age (years)
 Mean (SD) 70.1 (9.5) 73.6 (8.4) 69.8 (9.5) 69.4 (20.8) 0.46
Gender, n (%)
 Male 266 (81.6) 18 (81.8) 394 (83.1) 186 (83) 0.94
 Female 60 (18.4) 4 (18.2) 80 (16.9) 38 (17)
Smoking status
 Never 85 (26.1) 3 (13.6) 124 (26.1) 85 (38) < 0.001
 Current 136 (41.7) 6 (27.3) 243 (51.3) 100 (44.6)
 Former 105 (32.2) 13 (59.1) 107 (22.6) 39 (17.4)
Multifocality, n (%)
 Single 189 (58) 11 (50) 267 (56.3) 118 (52.7) 0.6
 Multiple 137 (42) 11 (50) 207 (43.7) 106 (47.3)
Size, n (%)
 < 3 cm 120 (36.8) 6 (27.3) 164 (36.4) 81 (36.2) 0.77
 ≥ 3 cm 206 (63.2) 16 (72.7) 310 (63.6) 143 (63.8)
Concomitant CIS, n (%)
 No 280 (85.9) 21 (95.5) 407 (85.9) 188 (83.9) 0.51
 Yes 46 (14.1) 1 (4.5) 67 (14.1) 36 (16.1)
Survival outcomes
Recurrence, n (%)
 No 231 (70.9) 20 (90.9) 98 (20.7) 19 (8.5) < 0.001
 Yes 95 (29.1) 2 (9.1) 376 (79.3) 205 (91.5)
Progression, n (%)
 No 271 (83.1) 20 (90.9) 302 (63.7) 150 (67) < 0.001
 Yes 55 (16.9) 2 (9.1) 172 (36.3) 74 (33)
Death 42 (12.9) 4 (18.2) 76 (16) 28 (12.5) 0.46
Death due to BC 20 (6.1) 2 (9.1) 36 (7.6) 19 (8.5) 0.77
510 World Journal of Urology (2019) 37:507–514
1 3
a normal BMI, 90.9% (CI 68.3–97.6) in patients with a 
BMI < 18.5, vs. 18.5% (CI 14.6–22.7) in overweight patients 
and 7.3% (CI 4.1–11.9) in obese patients. In the multivaria-
ble model, we found that tumor size [hazard ratio (HR): 1.3; 
p = 0.001] and multifocality (HR: 1.24; p = 0.004) were sig-
nificantly associated with recurrence (c-index 55.98). Over-
weight (HR: 4; p < 0.001) and obesity (HR:5.33 p < 0.001) 
were significantly associated with an increased risk of recur-
rence. Addition of the BMI to a model that included stand-
ard clinicopathological factors increased the C-index by 9.9 
(Table 2a).
In terms of progression, Kaplan–Meier survival analysis 
showed that overweight and obese patients had a signifi-
cantly shorter progression-free survival (PFS) than normal 
weight or underweight patients (p < 0.001, Fig. 1b). Five-
year PFS was 82.9% (CI 77.9–86.8) in patients with a normal 
BMI, 90.9% (CI 68.3–97.6) in patients with a BMI < 18.5, 
vs. 59.3% (CI 53.4–64.6) in overweight patients and 63.1% 
(CI 54.2–70.6) in obese patients. At multivariate analysis, 
tumor size (HR: 1.63; p < 0.001), multifocality (HR: 1.31; 
p = 0.01) and concomitant carcinoma in situ (CIS) (HR: 
2.07; p < 0.001) were significantly associated with progres-
sion (c-index 63.8). Overweight (HR: 2.52; < 0.001) and 
obesity (HR: 2.521 p < 0.001) were significantly associated 
with an increased risk of progression. Addition of the BMI 
to a model that included standard clinicopathological factors 
increased the C-index by 1.9 (Table 2b).
Association of the BMI with overall 
and cancer‑specific survival
Within a median follow-up of 48 months (IQR: 40–68), 
150 (14.34%) died due to overall causes, while 77 (7.36%) 
died of BC. At univariable and multivariable Cox regres-
sion analysis, the BMI was not a predictive factor for overall 
survival (OS) or for cancer-specific survival (CSS) (data not 
shown). Kaplan–Meier survival analysis did not show a sig-
nificance difference in survival among patients from differ-
ent BMI subgroups. Five-year OS was 88.8% (CI 83.8–92.3) 
in patients with a normal BMI, 77.1% (CI 42.3–92.4) in 
patients with a BMI < 18.5, 84.9% (CI 80.1–88.6) in over-
weight patients and 81.6% (CI 73–87.8) in obese patients. 
Five-year CSS was 96.3% (CI 92.8–98.1) in patients with 
a normal BMI, 88.8% (CI 43.3–98.3) in patients with a 
BMI < 18.5, 92.5% (CI 88.7–95) in overweight patients and 
88.1% (CI 80.4–92.9) in obese patients (Fig. 2a, b).
Discussion
In the current study, we evaluated the impact of the BMI on 
the oncological prognosis in patients affected by high-grade 
NMIBC. In particular, we showed that overweight (BMI 
25–29.9 kg/m2) and obesity (BMI ≥ 30 kg/m2) were asso-
ciated with a greater risk of progression. Instead, a higher 
risk of recurrence was demonstrated only for obese patients. 
Previous studies showed that a higher BMI was predictive 
of worse outcomes in subjects diagnosed with clinical T1 
high-grade NMIBC [8] and in patients who underwent radi-
cal cystectomy [3]. The association of obesity with a poor 
clinical outcome in T1G3 NMIBC could be explained on the 
basis of several factors. In particular, it is well known that 
obesity is characterized by insulin resistance and low-grade 
systemic inflammation, which may affect the oncological 
outcomes of NMIBC patients as a result of insulin, IGF-1, 
cytokines and growth factors’ effects [13]. In this regard, 
obese subjects showed increased levels of insulin and IGF-1 
[14]. Several epidemiological studies indicated that IGF-1 
played an important role in the incidence and progression of 
different types of cancer such as breast, prostate, lung, liver 
and colorectal cancers [15–18].
Furthermore, obesity is associated with high levels of 
inflammatory cytokines, such as leptin, IL-6 and TNF-α 
Fig. 1  Comparison of recurrence-free survival a and progression-free 
survival b according to BMI status
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produced by adipocytes and immune cells infiltrating adi-
pose tissue. Concurrently, lower amounts of adiponectin, 
an anti-inflammatory adipokine with anticancer properties, 
were released by adipocytes [19]. Such a systemic milieu 
produces a cancer-promoting microenvironment [20].
Indeed, several studies have already demonstrated a det-
rimental impact of obesity on oncological outcomes in blad-
der cancer.
In particular, Lin et  al. showed that the recurrence 
rate of bladder cancer was significantly higher in obese 
(HR  =  1.76, 95% CI 1.36–2.28) compared to normal weight 
patients. Stratification analysis showed that females had a 
higher risk of recurrence than males (HR  =  1.17, 95% CI 
1.05–1.31). Dose–response relationship analysis revealed a 
linear association between the BMI and risk of recurrence. 
Each 1  kg/m2 increase in BMI was related to a 1.3% 
increased risk of bladder cancer recurrence (HR  =  1.01, 
95% CI  =  1.01–1.02).
By contrast, there is a growing body of literature show-
ing a negative influence of obesity on genitourinary malig-
nancies [21]. Nevertheless, the data are not conclusive. For 
instance, Calle et al. carried out a large prospective study 
on 900,000 USA adults, investigating the role of obesity in 
the mortality risk of many types of cancer. Their findings 
showed that the risk of mortality of both prostate cancer and 
kidney cancer was significantly increased with increasing 
BMI values, whereas they did not find a significant associa-
tion with bladder cancer [22].
On the contrary, in a prospective study of 18,000 middle-
aged men, the authors showed an elevated risk of bladder 
Table 2  Univariable and multivariable Cox regression analyses predicting recurrence (A) and progression (B) in 1046 patients with primary 
T1G3 NMIBC treated with Bacillus Calmette–Guérin
Ref.: BMI 18.5–24.99 was used as a reference value
Bold values identify statistically significant variables
NMIBC non-muscle-invasive bladder cancer, CI confidence interval, HR hazard ratio, CIS carcinoma in situ, BMI Body mass index
A Recurrence-free survival
Variables Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age cont. 0.99 0.98–1 0.16 0.99 0.98–1 0.15
Gender (male vs. female) 1.24 1.03–1.49 0.02 1.08 0.9–1.31 0.37
Size (< 3 vs. ≥ 3) cm 1.28 1.09–1.51 0.002 1.3 1.1–1.53 0.001
Multifocality (single vs. multiple) 1.3 1.12–1.51 0.001 1.24 1.07–1.45 0.004
Concomitant CIS (no vs. yes) 1.17 0.95–1.44 0.13 1.13 0.91–1.39 0.23
Harrell’s C index 55.98
BMI Ref.
< 18.5 kg/m2 0.27 0.06–1.12 0.07 0.27 0.06–1.11 0.07
25–29.99 kg/m2 4.02 3.21–5.05 < 0.001 4 3.18–5.01 < 0.001
≥ 30 kg/m2 5.29 4.13–6.77 < 0.001 5.33 4.16–6.83 < 0.001
Harrell’s C index 65.88
B Progression-free survival
Variables Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age cont. 0.99 0.98–1 0.27 0.99 0.98–1 0.45
Gender (male vs. female) 1.35 1.03–1.77 0.02 1.22 0.92–1.61 0.15
Size (< 3 vs. ≥ 3) cm 1.78 1.37–2.3 < 0.001 1.63 1.26–2.11 < 0.001
Multifocality (single vs. multiple) 1.46 1.16–1.83 0.001 1.31 1.04–1.64 0.01
Concomitant CIS (no vs. yes) 2.19 1.69–2.85 < 0.001 2.07 1.59–2.7 < 0.001
Harrell’s C Index 63.8
BMI Ref.
< 18.5 kg/m2 0.56 0.13–2.33 0.43 0.64 0.15–2.66 0.54
25–29.99 kg/m2 2.50 1.84–3.39 < 0.001 2.52 1.85–3.42 < 0.001
≥ 30 kg/m2 2.51 1.77–3.58 < 0.001 2.51 1.76–3.57 < 0.001
Harrell’s C index 65.7
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cancer-related mortality in men who were either overweight 
(HR 1.68, 95% CI 1.06–2.65) or obese (HR 1.19, 95% CI 
0.27–5.18) [23].
With regard to the relationship between obesity and 
NMIBC, in a retrospective cohort study of 892 patients with 
primary superficial high-grade BCa, Kluth et al. showed that 
obesity was associated with an increased risk of disease 
recurrence (HR 2.66, 95% CI 2.12–3.32), disease progres-
sion (HR 1.49, 95% CI 1.00–2.21), cancer-specific mortal-
ity (HR 3.15, 95% CI 1.74–5.67) and any cause of mortal-
ity (HR 1.42, 95% CI 1.06–1.92) [8]. Similarly, in a USA 
population-based study of 726 patients with superficial BCa 
and a 6-year median follow up, Wyszynski et al. reported 
that high BMI values at diagnosis were associated with a 
modestly increased risk of recurrence (HR 1.33, 95% CI 
0.94–1.89) [24]. The same data also suggested that among 
current smokers, the risk of recurrence was increased more 
than twofold in overweight as compared with the normal 
weight patients (HR 2.67, 95% CI 1.14–6.28).
Collectively, the results obtained in our study in agree-
ment with others suggest that urologists should adopt a 
prudent policy for T1G3 NMIBC obese patients. Subjects 
with BMI values higher than 25 kg/m2 should be invited 
to undergo a weight loss program in order to improve their 
cancer-specific outcomes. Since the incidence of obesity 
is on the rise, increasing numbers of obese subjects may 
be expected to develop bladder cancer, so an elevated BMI 
should be considered as a relevant factor when clinicians are 
choosing the best therapeutic strategy.
Our study suffers from some limitations. Firstly, the study 
design is multicentric and retrospective, so it includes selec-
tion bias. There may be different treatment patterns across 
centers, the pathological evaluation was not centralized and 
various different surgeons were involved. Moreover, some 
metabolic phenotype details such as glycemic control and 
dyslipidemia were not available. This is a relevant issue, 
since type two diabetes, which is often diagnosed in obese 
subjects, has been shown to be an independent factor wors-
ening the oncological outcome of bladder cancer patients 
[25].
Further studies are warranted to evaluate whether a BMI 
evolution during follow-up significantly affects clinical 
outcomes.
Conclusion
The BMI seems to be associated with bladder cancer recur-
rence and progression. Taking into account this anthropo-
metric factor at the initial diagnosis and when planning the 
therapeutic strategy could be relevant in the clinical manage-
ment of T1G3 NMIBC. Future studies are needed to better 
define the impact of the BMI in clinical decision making for 
these patients.
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